Metformin is an oral antidiabetic drug that improves control of glycemia primarily by inhibiting hepatic gluconeogenesis and glycogenolysis. The common concept of initiating metformin for the treatment of pre-diabetic state, as the only effective measure seems to be limited with the findings of this study. After 1 year of metformin administration, a significant thyrotropin (TSH) decrease (P < 0.001) was observed in diabetic subjects with hypothyroidism who were either treated (n = 29; from 2.37 ± 1.17 to 1.41 ± 1.21 mIU/l) or untreated (n = 18; 4.5 ± 0.37 vs. Crandall. A secondary analysis compared the 342 patients allocated metformin with 951 overweight patients allocated intensive blood-glucose control with chlorpropamide (n=265), glibenclamide (n=277), or insulin (n=409). In the phase 1 trial, the researchers compared single daily doses of Metformin DR to immediate-release metformin (Metformin IR) and extended-release metformin (Metformin XR) in 20 healthy subjects who were each randomly assigned to receive one of the three treatments. T.N. Nonetheless, this apparent convergence of evidence from both observational and laboratory studies has led some to call for large randomized clinical trials (RCTs) of metformin in cancer prevention and treatment (6–9). Metformin also reduces insulin resistance and appetite and lessens glucose production by the liver, he notes, suggesting that more trials are necessary to evaluate the effects of the drug in overweight adolescents with Type 1 diabetes before prescribing practices are changed.